['respiratory syncytial virus']
['placebo', 'medi8897 10 mg', 'medi8897 25 mg', 'medi8897 50 mg']

        Key Inclusion Criteria:

          -  Healthy infants born between 32 weeks 0 days and 34 weeks 6 days gestational age

          -  Infants who are entering their first RSV season at the time of screening

        Key Exclusion Criteria:

          -  Gestational age < 32 weeks 0 days and >34 weeks 6 days

          -  Meets AAP or other local criteria to receive commercial palivizumab

          -  Any fever (≥ 100.4°F [≥ 38.0°C], regardless of route) or lower respiratory illness
             within 7 days prior to randomization

          -  Acute illness (defined as the presence of moderate or severe signs and symptoms) at
             the time of randomization

          -  Active RSV infection (a child with signs/symptoms of respiratory infection must have
             negative RSV testing) or known prior history of RSV infection

          -  Receipt of palivizumab or any RSV vaccine, including maternal RSV vaccination
      